SCHEMBL2375182

SCHEMBL2375182

COC(=O)[C@H](CO)N(Cc1ccc(-c2ccncc2)cc1)C(=O)C=Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 4/20 0.46
NOS1 P29475 4/20 0.46
NOS2 P35228 4/20 0.46
HTR5A P47898 2/20 0.41
NR1H4 Q96RI1 3/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
HDAC3 O15379 1/20 0.39
ADAM17 P78536 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
MMP1 P03956 1/20 0.38
CYP1A2 P05177 1/20 0.38
MAOB P27338 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375181 1.00 NOS3 (0.46) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2375187 1.00 NOS3 (0.46) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2375200 0.91 NOS3 (0.46) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2375206 0.91 NOS3 (0.46) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2375197 0.91 NOS3 (0.46) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2375592 0.90 NOS3 (0.44) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2375587 0.90 NOS3 (0.44) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2375583 0.90 NOS3 (0.44) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2374716 0.88 NOS3 (0.44) NOS3NOS1NOS2HTR5ANR1H4
SCHEMBL2373647 0.87 NOS3 (0.42) NOS3NOS1NOS2HTR5ANR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 NOS3 783/4885NOS1 996/4885NOS2 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.